Jančorienė, L.; Rozentāle, B.; Tolmane, I.; Jēruma, A.; Salupere, R.; Buivydienė, A.; Valantinas, J.; Kupčinskas, L.; Šumskienė, J.; Čiupkevičienė, E.; Ambrozaitis, A.; Golubovska, O.; Moroz, L.; Flisiak, R.; Bondar, B.
(Medicina, 2023)
Background and objectives: Since 2013, highly effective direct-acting (DAA) chronic hepatitis C (CHC) antiviral therapy became available, which has cure rates of over 95%. For choice of optimal CHC treatment, assessment ...